WHEAT RIDGE, CO / ACCESS Newswire / August 13, 2026 / Lifeloc Technologies, Inc. (OTCID:LCTC), a global leader in the development and manufacturing of breath alcohol and drug testing devices, has announced financial results for the quarter ended June 30, 2026.

Second Quarter Financial Highlights

Lifeloc posted quarterly net revenue of $2.445 million in the second quarter of 2026, resulting in a quarterly net loss of $(134) thousand, or $(0.05) per diluted share. These results compare to net revenue of $2.219 million and quarterly net loss of $(394) thousand, or $(0.14) per diluted share in the second quarter of 2025. Revenue for the quarter grew 10% versus the second quarter last year. Six-month net revenues of $4.739 million and a net loss of $(287) thousand, or $(0.10) per diluted share, compared to net revenue of $4.496 million and a net loss of $(686) thousand, or $(0.25) per diluted share, for the same period in 2025. Total gross margin in the second quarter rose to 45% versus 42% for the same quarter last year. For the first six months of 2026, gross margin was 44% versus 41% for the same period last year, with price increases and a favorable product mix contributing to the higher margins. The research and development investment for the quarter remained high at $560 thousand, primarily for SpinDetect™ analyzer development, resulting in the current period loss.

Alcohol Detection Products

We believe our core alcohol detection product line-up is strong. The L-series LX9 and LT7 units have features and performance that drive market penetration by meeting previously unaddressable market needs, such as smart phone pairing, wider temperature use ranges and fast customization that incorporates local languages. We expect that sales of our newer L-series devices will be incremental to FC-series devices rather than displacing FC sales. The L-series devices have been certified to meet the requirements of most modern registration standards, such as the latest AS 3547:2019 standards for Breath Alcohol Detectors from SAI Global (formerly Standards Australia International). Our FC-series devices remain popular with many law enforcement and international organizations. Our Easycal^® automated calibration station, the only automated calibration available for portable breath alcohol testers, builds valuable protection around our brand and has contributed to market share gains across the board, especially for our workplace Phoenix^® 6.0 BT and EV 30 devices.

SpinDetect™ Analyzer Platform

We believe our most significant long-term opportunity lies at the intersection of the global need for rapid, quantitative drug detection and our proven expertise in portable testing instrumentation. Our SpinDetect^™ Centrifugal Drug Analyzer - sometimes referred to as "Lab on a Disk" - is designed to address this need, enabling rapid, on-site, quantitative drug testing for use at roadside, in emergency rooms, forensic labs, and workplace testing sites. We have demonstrated the platform's ability to effectively detect delta-9-THC, cocaine, fentanyl, amphetamine/methamphetamine, morphine, MDMA, and benzodiazepines from oral fluid. We have validated our test results against liquid chromatography-mass spectrometry (LC-MS) - the definitive laboratory standard - using real-world human saliva samples, confirming a limit of detection of approximately 10 ng/ml.

We have completed the design of the SpinDetect^™ microfluidic disk, with all analytical chemistry now occurring on the disk after sample introduction. Disk design represented the primary technical challenge throughout the project, requiring specialized outside expertise and multiple design iterations. Disks have been molded and assays loaded for evaluation, with final component and process optimization ongoing. Reader hardware, firmware, drug assays, and reagent handling have been developed in parallel and are substantially complete. We will be initiating beta testing of the oral-fluid analyzer, focused on delta-9-THC detection using a prototype reader, under a signed beta-testing agreement, and are now targeting a limited commercial launch in Q1 of 2027.

"It is great to see assays performed with all the chemistry occurring on the disk. With our second dispensing robot scheduled for delivery later this month, we are moving closer to production," commented Dr. Wayne Willkomm, President and CEO. "Oral fluid drug screening will only be the first launching application of this technology platform. We expect subsequent releases to expand to additional drug panels and to samples collected from blood and breath, as well as to other applications, including select non-drug applications such as food pathogen detection."

Financing Update

During the quarter, Lifeloc closed on $500,000 of financing, securing a loan from our Chairman of the Board, who also serves as our Chief Financial Officer. This loan is detailed in our 8-K filing of May 8, 2026, and the key terms are 10.5% interest, adjustable upward based on the prime rate, interest only payments in 2026, followed by monthly payments that will result in the loan being fully paid in 5 years, and no prepayment penalty. The loan is secured by all of our assets. After exploring multiple financing options, the Company determined these terms were more favorable than alternatives available from commercial sources.

About Lifeloc Technologies

Lifeloc Technologies, Inc. (OTCID: LCTC) is a trusted U.S. manufacturer of evidential breath alcohol testers and related training and supplies for Workplace, Law Enforcement, Corrections and International customers. Lifeloc stock trades over-the-counter under the symbol LCTC. We are a fully reporting Company with our SEC filings available on our web site, www.lifeloc.com/investor.

Forward Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which involve substantial risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. All forward-looking statements expressed or implied in this press release, including statements about our strategies, performance, expectations about new and existing products, market demand, economic conditions, acceptance of new and existing products, technologies and opportunities, market size and growth, market liquidity for our shares, and return on investments in products and market, are based on information available to us on the date of this document, and we assume no obligation to update such forward-looking statements. Investors are strongly encouraged to review the section titled "Risk Factors" in our SEC filings.

Phoenix^® and Easycal^® are registered trademarks of Lifeloc Technologies, Inc.

SpinDetect^™ is a trademark of Lifeloc Technologies, Inc.

Amy Evans
Lifeloc Technologies, Inc.
http://www.lifeloc.com
(303) 431-9500

LIFELOC TECHNOLOGIES, INC.
Condensed Balance Sheets (Unaudited)

LIFELOC TECHNOLOGIES, INC.
Condensed Statements of Profit (Loss) (Unaudited)

LIFELOC TECHNOLOGIES, INC.
Condensed Statements of Profit (Loss) (Unaudited)

Lifeloc Technologies, Inc.
Condensed Statements of Changes in Stockholders' Equity (Unaudited)
For the Three and Six Months Ended June 30, 2026 and 2025

LIFELOC TECHNOLOGIES, INC.
Condensed Statements of Cash Flows (Unaudited)

SOURCE: Lifeloc Technologies, Inc.